Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22887712 | 1.00 | FAAH (0.42) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL459389 | 0.95 | FAAH (0.44) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL8217007 | 0.93 | FAAH (0.43) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL24753945 | 0.81 | PTPN1 (0.52) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL14417106 | 0.81 | ALDH1A1 (0.41) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| Mertiatide SCHEMBL136462 | 0.81 | ALDH1A1 (0.41) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL1493216 | 0.81 | ALDH1A1 (0.41) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL17177647 | 0.80 | FAAH (0.47) | FAAHALDH1A1KMT2ARECQLHDAC3 | |
| SCHEMBL2796838 | 0.79 | ALDH1A1 (0.40) | FAAHALDH1A1PTPN1MAPTTDP1 | |
| SCHEMBL25148092 | 0.79 | PTPN1 (0.50) | FAAHALDH1A1PTPN1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-11779602-B2 | Methods of use for CAR T cells | ENDOCYTE, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | ENDOCYTE, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3210627-B1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO LTD (CN) | 2022-12-21 | — | — | EP | disclosed |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | ENDOCYTE INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-11311576-B2 | Methods of use for CAR T cells | SEATTLE CHILDREN'S HOSPITAL (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210346431-A1 | SEQUENCING METHOD FOR CAR T CELL THERAPY | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2021-11-11 | — | — | US | disclosed |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2021-05-27 | — | — | US | disclosed |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2021-05-27 | — | — | US | disclosed |
| EP-3777898-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-7601332-B2 | Minimized toxicity; eliminating pathogenic cell populations; synthesis; claimed intermediates | ENDOCYTE, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| WO-2009002993-A1 | CONJUGATES CONTAINING HYDROPHILIC SPACER LINKERS | ENDOCYTE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | ENDOCYTE, INC. | 2008-10-09 | — | — | US | disclosed |
| WO-2008112873-A2 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | ENDOCYTE, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007022494-A2 | MULTI-DRUG LIGAND CONJUGATES | ENDOCYTE, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007022493-A2 | LIGAND CONJUGATES OF VINCA ALKALOIDS, ANALOGS, AND DERIVATIVES | ENDOCYTE, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311576-B2 | Methods of use for CAR T cells | CD47, CD4, CD2 | FAAH 2918/4885ALDH1A1 1822/4885PTPN1 3889/4885 |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | FAAH 2613/4885ALDH1A1 931/4885PTPN1 3504/4885 |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FAAH 2329/4885ALDH1A1 642/4885PTPN1 2631/4885 |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | VDR, HCAR1, FOLR1 | FAAH 2537/4885ALDH1A1 661/4885PTPN1 3980/4885 |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FAAH 2329/4885ALDH1A1 642/4885PTPN1 2631/4885 |
| US-11759480-B2 | Compositions and methods for CAR T cell therapy | CD47, PBK, GZMB | FAAH 3503/4885ALDH1A1 4160/4885PTPN1 1580/4885 |
| US-11779602-B2 | Methods of use for CAR T cells | CD47, CD4, CD2 | FAAH 2918/4885ALDH1A1 1822/4885PTPN1 3889/4885 |
| US-20220175875-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | FAAH 297/4885ALDH1A1 1100/4885PTPN1 4479/4885 |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | VDR, HCAR1, FOLR1 | FAAH 4328/4885ALDH1A1 247/4885PTPN1 4771/4885 |
| US-20210346431-A1 | SEQUENCING METHOD FOR CAR T CELL THERAPY | CD47, MCTS1, GZMB | FAAH 3483/4885ALDH1A1 4205/4885PTPN1 2745/4885 |
| US-20100048490-A1 | BINDING LIGAND LINKED DRUG DELIVERY CONJUGATES OF TUBULYSINS | TEK, TEKT1, VDR | FAAH 4730/4885ALDH1A1 4606/4885PTPN1 2529/4885 |
| US-11834406-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | FAAH 4558/4885ALDH1A1 3232/4885PTPN1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.